Wellgistics Health (WGRX) raises $1.25M via 0% notes with covenants
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Wellgistics Health, Inc. entered into a Note Purchase Agreement on April 1, 2026 to issue and sell up to $1,250,000 in aggregate principal amount of promissory notes in a private offering. Investors will pay $1,000,000, reflecting a 20% original issue discount.
The Notes bear 0% interest unless an event of default occurs, in which case interest increases to 15% per year. All principal and any default interest are due on the earlier of 12 months from issuance or the closing of a Qualified Financing. While the notes are outstanding, the company has agreed not to incur additional borrowed money debt or grant new liens, and investors receive the right to participate in future securities offerings up to 100% of their note principal.
Positive
- None.
Negative
- None.
Insights
Wellgistics raises discounted short-term debt with tight leverage limits.
Wellgistics Health, Inc. agreed to sell up to $1,250,000 in promissory notes for aggregate proceeds of $1,000,000, using a 20% original issue discount instead of a stated cash interest coupon. The notes mature on the earlier of 12 months from issuance or a Qualified Financing.
The structure keeps stated interest at 0% but embeds yield through the discount and a 15% default rate. While the Aggregate Principal Amount is outstanding, the company cannot incur additional borrowed money debt or grant new liens, which constrains incremental leverage but may reassure these investors.
Investors also receive participation rights in any future securities offering up to 100% of their purchased note principal. Actual impact will depend on whether a Qualified Financing occurs before the 12‑month maturity and how strictly the no‑new‑debt and no‑new‑lien covenants affect operating flexibility.
8-K Event Classification
4 items: 1.01, 2.03, 3.02, 9.01
4 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 2.03
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Financial
The company incurred a new significant debt or off-balance-sheet obligation.
Item 3.02
Unregistered Sales of Equity Securities
Securities
The company sold equity securities in a private placement or other unregistered transaction.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Aggregate principal amount of notes: $1,250,000
Aggregate purchase price: $1,000,000
Original issue discount: 20%
+4 more
7 metrics
Aggregate principal amount of notes
$1,250,000
Maximum principal under Note Purchase Agreement
Aggregate purchase price
$1,000,000
Total paid by investors for the notes
Original issue discount
20%
Difference between principal and purchase price
Normal interest rate
0% per annum
Interest on notes absent default
Default interest rate
15% per annum
Interest rate if an event of default occurs
Maturity
12 months
Due on 12‑month anniversary of issuance or Qualified Financing
Participation right
Up to 100%
Right to buy in Future Offerings up to 100% of purchased note principal
Key Terms
Note Purchase Agreement, original issue discount, Qualified Financing, Future Offering, +2 more
6 terms
Note Purchase Agreement financial
"entered into a note purchase agreement (the “Note Purchase Agreement”) with certain investors"
A note purchase agreement is a contract where an investor buys a company’s promissory note — essentially an IOU promising repayment with interest — instead of buying equity. It matters to investors because it defines the borrower’s repayment schedule, interest rate and legal protections, so it affects expected returns, risk of loss, and where the investor stands compared with shareholders or other creditors if the company runs into trouble.
original issue discount financial
"The aggregate purchase price payable by all Investors for the Notes is $1,000,000, reflecting a 20% original issue discount."
Original issue discount (OID) is the difference between a debt security’s face value and the lower price at which it is first sold, treated as additional interest that accrues over the life of the instrument. For investors it matters because OID raises the effective yield and changes taxable income and the holding’s cost basis over time — think of buying a $100 voucher for $90 and recognizing the $10 gain as earned interest as the voucher approaches maturity.
Qualified Financing financial
"the date of closing of the next issuance and sale of capital stock of the Company... to Investors (a “Qualified Financing”)."
Future Offering financial
"if the Company proposes to offer and sell its securities... (each, a “Future Offering”)"
accredited investor regulatory
"each Investor represented to the Company... that it is an “accredited investor”"
An accredited investor is an individual or entity that meets certain financial criteria, such as having a high income or significant net worth, allowing them to invest in private or less regulated investment opportunities. This status matters because it grants access to investments that are often riskier or less available to the general public, reflecting a higher level of financial knowledge or resources.
Rule 506(b) of Regulation D regulatory
"in reliance upon the exemptions from the registration requirements... and Rule 506(b) of Regulation D thereunder."
Rule 506(b) of Regulation D is a set of rules that allows companies to raise money from investors without having to register with the government, as long as they follow certain guidelines. It lets companies offer securities to a limited number of investors, often trusted or experienced ones, making it easier and quicker to raise funds compared to traditional methods. This rule matters to investors because it provides access to private investment opportunities that are generally less regulated but still require careful consideration.
FAQ
What financing did Wellgistics Health (WGRX) enter into on April 1, 2026?
Wellgistics Health entered a Note Purchase Agreement to issue up to $1,250,000 in promissory notes. Investors will pay $1,000,000 in total, reflecting a 20% original issue discount in a private offering exempt from Securities Act registration.
How are the Wellgistics Health notes priced and what is the original issue discount?
The notes have an aggregate principal amount of $1,250,000, but investors pay $1,000,000. This difference represents a 20% original issue discount, providing investor return through discounted purchase instead of ongoing stated interest payments under normal conditions.
What interest rate and default rate apply to the Wellgistics Health notes?
The notes accrue interest at 0% under normal conditions. If an event of default occurs, the interest rate increases to 15% per annum. Specified default events include bankruptcy and insolvency, after which investors may demand immediate repayment of outstanding principal.
When do the Wellgistics Health notes mature or become payable?
All principal and any applicable interest on the notes are due on the earlier of the 12‑month anniversary of issuance or the closing of a Qualified Financing. A Qualified Financing is the next issuance and sale of the company’s capital stock in specified transactions.
What restrictions does Wellgistics Health face while the notes are outstanding?
While the Aggregate Principal Amount remains outstanding, Wellgistics has agreed not to incur borrowed money debt or issue debt securities and not to grant new liens or security interests on its assets. These covenants limit additional leverage and secured financing.
What participation rights do Wellgistics Health note investors receive in future offerings?
For at least one year after issuance, or as long as any notes remain outstanding, investors may participate in any Future Offering. They can buy securities in an amount up to 100% of their purchased note principal, though exercising this right is optional.
Under what securities law exemptions are the Wellgistics notes being issued?
The notes, any securities issued upon conversion, and PA Warrants are being sold in reliance on Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D. Each investor represented that it is an accredited investor under Rule 501(a)(3).